Great Partnerships Enable Greater Solutions
Our partnerships help us offer next-level solutions so we continue to lead the industry with an innovative approach to going label-free. Find out how our partnerships are helping us set a gold standard at SAMDI Tech.
The mission of the National Cancer Institute’s Experimental Therapeutics Program (NExT) is to advance clinical practice and bring improved therapies to patients with cancer by supporting the most promising new drug discovery and development projects. SAMDI Tech’s label-free assay platform is an important tool in the NExT pipeline for the discovery of novel small molecule inhibitors for next generation cancer targets.
Confluence Discovery Technologies delivers custom research solutions, specializing in complex biological systems, challenging drug target inhibitory mechanisms and preclinical and clinical biomarker development. Through this partnership, SAMDI Tech and Confluence offer a range of services from drug discovery to preclinical development, combining their expertise to provide a comprehensive solution from HTS and follow-up through structure-based drug design, cell-based assays and in vivo pharmacology.
Established in Kiev, Ukraine, in 1991, Enamine is a chemical company producing building blocks and screening libraries of world reputation. The major asset of the company is the world’s largest collection of building blocks: 150,000 in stock with 2,000 additions synthesized each month. These research functionalized compounds provide a significant competitive advantage to the company in supplying custom compound libraries particularly in the frame of medicinal chemistry collaborations and compound collection enhancement programs. Enamine’s REAL (readily accessible) concept is based on the careful and knowledge-guided enumeration and selection of compounds that can be confidently produced from the stock building blocks using more than 100 validated reaction protocols.